Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 29%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc has demonstrated a positive financial trajectory, evidenced by an improved gross margin year-over-year, largely driven by a greater proportion of consumables revenue. The company has reported increased utilization of its Revio sequencing platform, reaching its highest levels since launch, which suggests robust demand for its products. Additionally, management anticipates sequential growth in Vega placements throughout the year, indicating a strong outlook for large-scale projects and overall business expansion.

Bears say

Pacific Biosciences of California Inc is facing a negative outlook due to an anticipated decline in gross margins, projected to fall below the 40.4% reported in the previous quarter. Additionally, there are concerns regarding stagnant utilization rates and weaker than expected demand for new instruments, potentially jeopardizing the company's financial targets for 2026. Furthermore, ongoing demand weakness in the critical market of China is expected to continue throughout 2023 and into 2024, further impacting the company's performance.

PACB has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 7 analysts, PACB has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.